Phase II clinical trial of new indication of siliquax, a new class I new drug of tailing medicine, approved

Phase II clinical trial application for new indication of myelodysplastic syndrome (MDS) of uropolypeptide injection, a new drug of thaling Pharmaceutical Group, has been approved by the State Food and Drug Administration recently At present, siliquac is used for adjuvant treatment of advanced non-small cell lung cancer and breast cancer patients, and has been put on the market At present, siliquac is one of the few drugs approved for clinical research and treatment of MDS patients MDS is a malignant clonal disease characterized by different degrees of peripheral blood cell reduction accompanied by ineffective hematopoiesis of bone marrow About one third of patients will develop into acute myeloid leukemia after several months to several years At present, MDS is still considered as an incurable disease in the world According to the industry estimates, the incidence rate of myelodysplastic syndrome in mainland China has reached 3/100000, and the average age of onset of the disease is ten years younger than that in western countries Established in 1995, China tailing Pharmaceutical Group Co., Ltd is the largest third-party marketing service provider of drugs and vaccines in China The group was listed on the main board of the stock exchange of Hong Kong on April 20, 2011, with stock number of 1011.hk In May 2013, tailing pharmaceutical purchased intellectual property rights of uropolypeptide injection (cedik) from Hefei Yongsheng pharmaceutical with 30.5 million yuan, mainly used to treat malignant lung and breast tumors CDA-2 bulk drug injection capsule obtained the approval of new drug clinical research in 1999, completed phase III clinical trial at the end of 2002, obtained the approval of drug registration and new drug certificate in August 2004, applied for GMP certification at the same time and obtained GMP certificate at the end of the year.